Sustained Systemic Delivery of Monoclonal Antibodies by Genetically Modified Skin Fibroblasts

This publication has 23 references indexed in Scilit:

• Development of Cellulose Sulfate‐based Polyelectrolyte Complex Microcapsules for Medical Applications
  Annals of the New York Academy of Sciences, 1999
• In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices
  Journal of Molecular Medicine, 1999
• Cell targeting by murine retroviral vectors
  Critical Reviews in Oncology/Hematology, 1998
• IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
  Blood, 1997
• Increased clearance of IgG in mice that lack β₂‐microglobulin: possible protective role of FcRn
  Immunology, 1996
• Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease
  Immunological Reviews, 1995
• Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs
  Nature Medicine, 1995
• Idiotypic Restriction of Murine Monoclonal Antibodies to a Defined Antigenic Region of Human Thyroglobulin
  Immunological Investigations, 1995
• Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy
  Nucleic Acids Research, 1992
• Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.
  Molecular and Cellular Biology, 1986